Study: Less-Invasive Mesothelioma Surgery Yields Better Results

A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower surgical risk without compromising survival in patients with malignant pleural mesothelioma.” The focus on finding less-invasive and better-tolerated pleural mesothelioma surgery techniques is important for improving outcomes of patients diagnosed with this asbestos-related cancer. Less Is More with Mesothelioma Surgery In the study, researchers collected information on nearly every mesothelioma patient scheduled to undergo surgery at their facility between April 2004 and July 2016. Of the 152 patients, 117 received one of three surgical procedures: Group 1 underwent conventional extrapleural pneumonectomy Group 2 received less-invasive extrapleural pneumonectomy Group 3 underwent a pleurectomy and decortication 
 Nearly all of the patients — 92 percent of them — were diagnosed with epithelial cell mesothelioma. All but t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Tumor Treating Fields is one of the newest treatments on the market for pleural mesothelioma cancer patients with metastatic disease. The device is also available to patients with locally advanced cancer who are not candidates for mesothelioma surgery. Clinical trials of the treatment, previously known as NovoTTF-100L, extended the survival of mesothelioma patients by more than six months compared to those receiving only chemotherapy. The device is now called Optune Lua and has been available outside of clinical trials for over a year. More physicians and treatment centers are becoming certified to prescribe the treatmen...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T Abstract Objective: The purpose of the present review was to provide evidence-based guidance about the provision of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in the treatment of peritoneal cancers. Methods: The guideline was developed by the Program in Evidence-Based Care together with the Surgical Oncology Program at Ontario Health (Cancer Care Ontario) through a systematic review of relevant literature, patient- and caregiver-specific consultation, and internal and external reviews. Results: Re...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Patients with mesothelioma are being recruited by the National Cancer Institute for a phase II clinical trial using a novel immunotoxin prior to pembrolizumab, a combination that has shown preliminary evidence of efficacy. This promising mesothelioma clinical trial involves the drug LMB-100, designed to make immunotherapy agents such as pembrolizumab, otherwise known as Keytruda, more effective. NCI’s trial includes separate cohorts for pleural and peritoneal types of mesothelioma. “This is a very good option for these patients,” medical oncologist Dr. Raffit Hassan, an acclaimed investigator at the Natio...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Rare thoracic malignancies, those with an incidence lower than 6 per 100,000 as a threshold of rarity, include epithelial tumors of the trachea, thymus and malignant pleural mesothelioma (MPM). Foremost among these rare tumors is mesothelioma, accounting for 2.1 cases per 100,000 people per year [1]. While we are witnessing years of exciting progress for lung cancer patients, very few advances have been made in MPM since the approval of pemetrexed in 2004 [2]. Not surprisingly, life expectancy of MPM remains suboptimal with a median overall survival (OS) of less than 1  year and 5-year OS of approximately 5% [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
in Collins Andrew Churg Well-differentiated papillary mesothelioma (WDPM) is an uncommon mesothelial proliferation that is most commonly encountered as an incidental finding in the peritoneal cavity. There is controversy in the literature about whether WDPM is a neoplasm or a reactive process and, if neoplastic, whether it is a variant or precursor of epithelial malignant mesothelioma or is a different entity. Using whole exome sequencing of five WDPMs of the peritoneum, we have identified distinct mutations in EHD1, ATM, FBXO10, SH2D2A, CDH5, MAGED1, and TP73 shared by WDPM cases but not reported in malignant mesoth...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In conclusion, our study has identified that acidic mesothelioma milieu drives DC dysfunction and altered T cell response through pharmacologically reversible TGF-β2-dependent mechanisms.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract BRCA1-associated protein 1 (BAP1) is a deubiquitinating enzyme that has long been considered to be a tumor suppressor in various tumors, including renal cell carcinoma, uveal melanoma, mesothelioma, and cutaneous melanoma. However, the involvement of BAP1 in the progression of prostate cancer has not been studied until recently. Herein, we investigated the tumor promoting function of BAP1 in the context of prostate cancer. Analysis of The Cancer Genome Atlas (TCGA) data set showed that prostate cancer patients express high levels of BAP1 mRNA. High BAP1 expression is inversely correlated with disease-free survival...
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
Abstract Malignant mesothelioma (MM) is an aggressive asbestos-related cancer of the serous membranes. Despite intensive treatment regimens, MM is still a fatal disease, mainly due to the intrinsic resistance to current therapies and the lack of predictive markers and new valuable molecular targets. Protein arginine methyltransferase 5 (PRMT5) inhibition has recently emerged as a potential therapy against methylthioadenosine phosphorylase (MTAP)-deficient cancers, in which the accumulation of the substrate 5'-methylthioadenosine (MTA) inhibits PRMT5 activity, thus sensitizing the cells to further PRMT5 inhibition....
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
livier Coqueret Catherine Guette Daniel L. Pouliquen Recent findings suggest that S100A4, a protein involved in communication between stromal cells and cancer cells, could be more involved than previously expected in cancer invasiveness. To investigate its cumulative value in the multistep process of the pathogenesis of malignant mesothelioma (MM), SWATH-MS (sequential window acquisition of all theoretical fragmentation spectra), an advanced and robust technique of quantitative proteomics, was used to analyze a collection of 26 preneoplastic and neoplastic rat mesothelial cell lines and models of MM with increasing...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This study of women included 275 cases of pleural mesothelioma and 79 cases of peritoneal. Papillary mesothelioma and localized mesothelioma cases were excluded. Previous reports have shown that 22% to 29% of mesothelioma cases involve women, but only 12% in this particular study. Other Notable Takeaways The majority of those studied were exposed to asbestos through household contact. Women who worked in occupations and industries associated with higher asbestos exposure had objective markers of exposure similar to men. Survival was longer for the epithelial subtype of mesothelioma and magnified with the per...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Environmental Health | Epithelial Cancer | Heart | Japan Health | Mesothelioma | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study